"Our view is that you should definitely keep some glove stocks in your portfolio," said Maybank Kim Eng head of regional equity research Anand Pathmakanthan in a webinar session today titled "Market Outlook 2021: Steering through Volatility".

https://www.theedgemarkets.com/article/maybank-kim-eng-says-keep-some-glove-stocks-your-portfolio

The bosses acquired 300K shares today.

Tradeview Commentaries 4th January 2021 - A New Year, A Fresh Start

Dear all, the morning glove selloff may have panicked investors and triggered some margin call or panic selling. Just a quick update of our view, the short sellers who are selling off the glove stocks are not very smart. It is a risk to reward ratio for short term traders. Capitalizing on temporary fear versus eventual rationality is dangerous play.

However, this may not be a bad thing as it would mean that smart funds who can see the market irrationality would come in to scoop low. I foresee the yields on glove stocks to now exceed my earlier 7-8% in dividend yield based on today's pricing possibly hitting double digits already by now. At current share price valuation of the glove stocks, it is discounting entirely the years of supernormal profit of 2020-2022. In fact, it is cheap even by trailing historical valuation per se. In short it is severely undervalued.

The saying goes "the market can remain irrational longer than you can stay solvent". My take - if you as retail investors can stay solvent longer than market irrationality, you will come out the winner. Have faith in the fundamentals. Fundamentals never lie.

Source : www.tradeview.my

PUTRAJAYA: Despite claims made by some pharmaceutical companies on vaccine discovery and that third phase of it clinical trial has been completed, it is still a long way for it to be made available for Malaysia.

Health director-general Tan Sri Dr Noor Hisham Abdullah said currently there were 10 companies claiming to have come close to finding a vaccine. However none had actually published their clinical trial data to be reviewed.

"Some companies such as Pfizer and Moderna claimed to have found a vaccine and that they had completed phase three of the clinical trial. But until now, these companies have yet to publish the data from the clinical trials.

"There are also media reports saying that Covid-19 vaccine has been found, but that alone is not enough to convince its effectiveness or safety," Dr Noor Hisham said during a Covid-19 briefing session with the media here today.
He said reports that Pfizer had submitted their vaccine discovery to the US Food and Drug Administration (FDA) in the United States on Friday for approval, was only for clinical interim analysis report.

"It is not the data from the clinical trial that they allegedly carried out," he said.

He was responding to a question on how soon a vaccine would be available for Malaysia and if three was any preferred vaccine producer for the country.

Meanwhile, deputy director-general of Health Dr Hishamshah Mohd Ibrahim said vaccine approval was not a simple process, as it needed to undergo various levels of testing and approval from multiple agencies.

"These companies have yet to provide data from their clinical trials, as required by the World Health Organisation and relevant authorities.
"There are several stages of testing and reviews which the vaccine must first pass, before it can be certified as an effective and safe to use vaccine," he said.

For instance, Dr Hishamshah said, in Malaysia there is the Vaccine Supplies Access Guarantee Special Committee under the purview of Ministry of Science, Technology and Innovation comprising academicians, medical experts and professionals who will review vaccines approved by FDA, before it can be selected for use in Malaysia.

"As of now, there are no pharmaceutical companies that have successfully produced a Covid-19 vaccine, that has been backed by relevant empirical data.

"All those (reports) are mostly claims and media reports that have no published data of the trials conducted," Dr Hishamshah said.

It was reported today that US biotech giant Pfizer and German partner BioNTech had sought approval on Friday (Saturday in Malaysia) to roll out their coronavirus vaccine early.

Vaccines developed by BioNTech/Pfizer and Moderna are among those in the lead in the global race for Covid-19 vaccine.
https://www.nst.com.my/news/nation/2020/11/643137/covid-19-vaccine-malaysia-still-long-way-go

Based on the trading activities on glove counters with a positive start, there might be follow through support on the sector starting from this moment. The catalyst for the sector could be looking at higher combat actions of Covid-19 cases in the US which may translate to more demand of gloves as well as if there is a vaccine to be mass produce for the global population that will be additional gloves needed.

Source: M+ Online

https://klse.i3investor.com/blogs/eberthoNov2020/2020-11-16-story-h1536436998-BIG_4_Share_Price_where_are_we_now_H1N1_vs_COVID_19.jsp

https://klse.i3investor.com/blogs/eberthoNov2020/2020-11-16-story-h1536436998-BIG_4_Share_Price_where_are_we_now_H1N1_vs_COVID_19.jsp

The United States has so far reported over 150,000 new coronavirus cases, the highest daily figure anywhere in the world since the pandemic began.
Worldwide coronavirus cases pass 52.5 million

The United States has so far reported over 150,000 new coronavirus cases, the highest daily figure anywhere in the world since the pandemic began.
Worldwide coronavirus cases pass 52.5 million

Greeny day...

Greeny day...

KUALA LUMPUR (Nov 4): A windfall tax being imposed on the glove sector in Malaysia will be difficult to execute, opined CGS-CIMB Research, adding that should this materialise in the upcoming Budget 2021, it would likely be a one-off collection or payment to the government.

In a note today, CGS-CIMB said the difficulty is due to a lack of standardised pricing of gloves due to the variety in types, specifications and product grades as well as intended target markets.

Nevertheless, should this happen, it will have negative implications for the sector, particularly its long-term prospects, it said.

CGS-CIMB maintained "overweight" on the rubber glove sector.

The Malaysian government is set to table Budget 2021 on Friday (Nov 6). There have been growing concerns that the government would implement some sort of windfall tax on glove companies to shore up its coffers amid ongoing economic uncertainties.

This is in view of recent "supernormal" profits enjoyed by the glove sector, given the surge in both demand and average selling prices (ASPs) of gloves due to the Covid-19 pandemic, CGS-CIMB noted.

“For illustration purposes, we conducted a sensitivity analysis of the potential impact of a higher corporate tax rate. We found that a 5% rise in the corporate tax rate could cut the sector’s 2020 net profit by 6.5% and allow the government to raise an extra RM593 million in taxes for 2020.

"Based on our estimates, glove companies we cover are already slated to pay total corporate income tax of RM2.8 billion and RM4.7 billion for 2020 and 2021 [respectively], based on our forecasts,” it said.

If a windfall tax materialises, CGS-CIMB said it believes Malaysian glove makers may opt to expand overseas.

This could result in potential opportunity loss for the government due to lower future investment by glove players and its spillover benefits, it said.

KUALA LUMPUR (Nov 4): A windfall tax being imposed on the glove sector in Malaysia will be difficult to execute, opined CGS-CIMB Research, adding that should this materialise in the upcoming Budget 2021, it would likely be a one-off collection or payment to the government.

In a note today, CGS-CIMB said the difficulty is due to a lack of standardised pricing of gloves due to the variety in types, specifications and product grades as well as intended target markets.

Nevertheless, should this happen, it will have negative implications for the sector, particularly its long-term prospects, it said.

CGS-CIMB maintained "overweight" on the rubber glove sector.

The Malaysian government is set to table Budget 2021 on Friday (Nov 6). There have been growing concerns that the government would implement some sort of windfall tax on glove companies to shore up its coffers amid ongoing economic uncertainties.

This is in view of recent "supernormal" profits enjoyed by the glove sector, given the surge in both demand and average selling prices (ASPs) of gloves due to the Covid-19 pandemic, CGS-CIMB noted.

“For illustration purposes, we conducted a sensitivity analysis of the potential impact of a higher corporate tax rate. We found that a 5% rise in the corporate tax rate could cut the sector’s 2020 net profit by 6.5% and allow the government to raise an extra RM593 million in taxes for 2020.

"Based on our estimates, glove companies we cover are already slated to pay total corporate income tax of RM2.8 billion and RM4.7 billion for 2020 and 2021 [respectively], based on our forecasts,” it said.

If a windfall tax materialises, CGS-CIMB said it believes Malaysian glove makers may opt to expand overseas.

This could result in potential opportunity loss for the government due to lower future investment by glove players and its spillover benefits, it said.

Listing Date 05-Nov-2020
New type/class? No
Type Private Placement
Details PRIVATE PLACEMENT OF NEW ORDINARY SHARES IN CAREPLUS, REPRESENTING UP TO 10% OF THE TOTAL NUMBER OF ISSUED SHARES IN CAREPLUS (EXCLUDING TREASURY SHARES, IF ANY)
No. of shares issued 9,720,000
Issue Price Malaysian Ringgit (MYR) 3.600
Par Value - 0.000
Total NOSH 550,079,799

People just read the headlines without digesting it...

Market update: Based on the unchanged narrative on Covid-19 (still rising cases), couple with the observation on the Sputnik V vaccine (they claimed that they are the first registered vaccine against Covid-19, but I believe it has not gone into the mass production phase yet), Russia's daily confirmed cases and deaths are still rising. Hence, breaking of the Covid-19 cases as well as following the guidelines could be the only few ways to stop the virus transmission at this stage.

So, on that note, we think glove may continue its upward trending mode for now, while the glove proxies (chemical, hand formers producers), PPE, healthcare-related stocks could see some potential trading interest in the near term.

Potential stocks that may trade higher based on technical analysis:-

Glove: SUPERMX, CAREPLS, HLT
Glove proxies: LUXCHEM, SAMCHEM, ESCERAM
PPE: TEKSENG, NOTION
Rapid test kit: ACO
Medical equipment: LKL, BCMALL
Pharma or vaccine related: AHEALTH
Others: ASIAPLY, ADVENTA, MASTER, JAYCORP, EWEIN, TITIJYA

Source: M+ Online

"I believe I can fly....."

"strong, formidable, convincing" movement from Carepls today.

Add 30% from current price to limit up

https://www.tradingview.com/chart/CAREPLS/SnsJqBCo-CAREPLS-POTENTIALS/

Areca Capital Sdn Bhd chief executive officer Danny Wong Teck Meng said it is normal for investors to take profit on glove counters especially after the substantial gains in the past few months.

"When the prices keep on going up, there will be some profit-taking, so [a pullback of] anything between 15% and 20% is healthy.

"As we always look beyond the short term, I am pretty okay with glove counters' fundamentals as they are expected to continue to deliver good earnings in coming quarters. Hence, fundamentally speaking, I will still hold glove stocks," Wong added.

https://klse.i3investor.com/blogs/koonyewyinblog/

"I think all the glove stock prices corrections are overdone already. It is a good time to start buying back at cheaper prices."

Dream it. Believe it. Achieve it.

Buy, fastern your seat belt and hold until reach your personal target.

Covid case will increase when the temperature is lower...

PUTRAJAYA, 31 Ogos -- Kementerian Kesihatan (KKM) bersiap siaga menghadapi kemungkinan pertambahan kes COVID-19 dari luar negara dalam tempoh empat bulan akan datang apabila musim sejuk melanda negara-negara yang berkenaan.

Ketua Pengarah Kesihatan Tan Sri Noor Hisham Abdullah berkata walaupun jangkitan di dalam negara masih terkawal, berdasarkan pemantauan kes COVID-19 di negara-negara seperti India, Korea Selatan, Jepun, Sepanyol dan Perancis sekarang menunjukkan peningkatan seiring penurunan suhu di negara-negara terbabit.

"Jadi kebimbangan kita ialah apabila (tiba) musim sejuk, kes akan bertambah dan kita perlu membuat kesiapsiagaan," katanya ketika ditemui Bernama selepas menghadiri sambutan Hari Kebangsaan 2020 di Dataran Pahlawan Negara, di sini hari ini.

3.64

Zooommm...sudah hijau.

https://onedelta.app/community/question/75096

Glove is still worth to all-in! don't worry

"The astonishing rally in Asian glove-maker stocks will extend further, as the coronavirus-led boom in demand shows no sign of abating, according to Citigroup Inc. Malaysia’s Top Glove Corp. and Kossan Rubber Industries can each climb by about 75% over the next 12 months as the pandemic drives unprecedented growth in sales and profits for the sector, Megat Fais, an analyst, wrote in a note on Tuesday."

"..As I said earlier, glove stocks will continue to go up higher and higher until the pandemic is under control which will take at least 1 more year. Even if the vaccine is proven to work, it will take a long time to produce enough of vaccine to vaccinate everybody in the whole world. Even if all the people in the whole world are vaccinated, the demand for glove will not be reduced so quickly to affect the share prices..."

https://klse.i3investor.com/blogs/koonyewyinblog/2020-08-14-story-h1511705723-Some_useful_tips_for_investors_Koon_Yew_Yin.jsp

Catch the falling knife if you wear "thick glove"..

https://www.facebook.com/TheStarOnline/videos/343601736663274

Top up!

"Glove counters fell sharply again today after Friday’s losses, raising the question of whether the rally fueled by soaring glove demand since the start of the Covid-19 pandemic is over.

Not so, said an analyst who believes the rally is still intact."

https://www.theedgemarkets.com/article/rally-still-intact-analyst-says-after-glove-counters-decline-two-days?type=malaysia

Wow...banyak jahat ini market operator.

Aduii...

Re post. Given the surge in demand for rubber gloves amid the COVID-19 pandemic, Careplus said it is expecting strong positive results during the pandemic and beyond.
“Careglove sales outside of Brazil have increased significantly while the Brazilian sales have also turned around significantly with better margins.
While spot average selling price (ASP) remain high, the ASP for regular buyers is expected to increase in the coming quarter barring any significant change to current shortage of supply.
“The COVID-19 pandemic has accelerated our plan to increase the production capacity for the Group subsidiaries,” it said.
The group noted that by the end of the year, 10 new production lines will be installed and commissioned, with another 13 new production lines are to be installed and commissioned during 2021.
Consequently, it will double its total production capacity to 8.8 billion pieces by end-2021 from 4.1 billion pieces currently – with a total of 50 production lines by the end of next year.
Moreover, by converting its existing dormant warehouse into Factory 2, it will see an additional six new production lines with an annual capacity of 1.08 billion pieces per annum. The total estimate capital expenditure (capex) is RM31.5 million, with the project wholly-operated and owned by its unit, Rubbercare Protection Products Sdn Bhd.
Careplus also referenced its recent purchase of a 90% stake in Centro Heights Sdn Bhd – the proprietor of a budget hotel and adjoining shop lot – to create a worker’s hostel with Centro Height’s property, saying Tang Kin San, who owns the remaining 10% stake, has an option to purchase a 20% stake from the group in the next five years.

Everyday got private placement. Hmm...

Can collect for long term investment if you have extra money.

MCT - Trading Halt and Resumption of Trading
ILC-01072020-00008
Kindly be advised that trading in MCT?s shares will be halted with effect from
9.00 a.m., Wednesday, 1 July 2020. Trading in the shares will resume with
effect from 10.00 a.m., Wednesday, 1 July 2020. Your attention is drawn to
the Company's announcement dated 1 July 2020.

Why suspend?

https://klse.i3investor.com/servlets/ptres/55671.jsp

Climbing up...

So can continue to buy and hold MCT...

Berdasarkan pengumuman PM sebentar tadi, ada tiga point menarik untuk hartanah:-

1 - Tak kena duti setem untuk harga rumah RM300k sehingga RM2.5 juta (sebelum ni tak kena duti setem untuk rumah harga sehingga RM300k sahaja)
2 - Boleh waive RPGT untuk tiga buah rumah untuk individu (sebelum ni satu rumah sahaja boleh waive)

3. Meningkatkan had pembiayaan hartanah ketiga bagi hartanah berharga lebih RM600k. Boleh dapat 90% pembiayaan untuk rumah ketiga. (Sebelum ni rumah ketiga boleh dapat 70% pembiayaan sahaja)

Buy!

Long weekend/holiday. Take a break for awhile. Next Tuesday will move up..

Why so quiet?. MCT is moving guys...